Cure My Disease

Don't miss your cure!

 Log in / Sign up

Double immune blockade aims to flush out hidden HIV

NCT ID NCT07692932

Cure Sponsor: Cliniques universitaires Saint-Luc- Université Catholique de Louvain Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 09, 2026 · Last updated Jul 10, 2026 · Updated 1 time

Summary

This study investigates whether combining two immune checkpoint inhibitors—one targeting GARP:TGF-β1 and another targeting PD-1—can better reactivate and eliminate dormant HIV-infected cells. Using blood samples from people with HIV-1 on suppressive antiretroviral therapy, researchers will measure if this 'shock-and-kill' approach reduces the viral reservoir and boosts immune responses. The goal is to find a strategy that could lead to an HIV cure.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
GARP:TGF-β1 and PD-1 blockade (immune checkpoint inhibitors)
What this could lead to
If successful, this approach could significantly shrink the hidden HIV reservoir, bringing us closer to a functional cure for HIV-1.
What could go wrong
This is an early ex vivo study using blood samples, not a full human trial. The combination may not work as hoped or could cause immune-related side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2026

An estimate. Start dates often move.

Expected to finish

Dec 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults (min 18 years old). * HIV-1 subtype B infected and regularly followed at Centre de reference HIV of Cliniques Universitaires Saint-Luc. * Treated on cART and virologically suppressed. Exclusion Criteria: * Elite controlers * Recent viral blip (defined as HIV-1 viral load in plasma 30-200 copies/ml, \< 6 months prior to study inclusion) * Chronic hepatitis B or C co-infection. * Acute illness at the time of inclusion. * Immunosuppressive or immunomodulatory treatment or condition, active or expected to have a residual activity at time of inclusion. * Pregnancy at the time of inclusion. * Vulnerable subjects.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV-1-infection are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV-1-infection

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Cliniques Universitaires Saint-Luc

    Brussels, Brussels Capital, 1200, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.